Cargando…

Target Points in Trastuzumab Resistance

Epidermal growth factor (EGF) family of receptors is involved in cell growth and differentiation. The human EGF2 (HER2) lacks natural ligands, and correlation between HER2 levels and carcinogenesis makes the receptor an ideal candidate for targeted therapy in breast cancer. Trastuzumab is a humanize...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shojaei, Sahar, Gardaneh, Mossa, Rahimi Shamabadi, Abbas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3299266/ https://www.ncbi.nlm.nih.gov/pubmed/22482061 http://dx.doi.org/10.1155/2012/761917

Ejemplares similares

Umbilical cord: an unlimited source of cells differentiable towards dopaminergic neurons
por: Boroujeni, Mahdi Eskandarian, et al.
Publicado: (2017)

The effect of Carbaryl on the pituitary-gonad axis in male rats
por: Fattahi, Esmail, et al.
Publicado: (2012)

Resistance to Trastuzumab
por: Vivekanandhan, Sneha, et al.
Publicado: (2022)

The Effect of 8-Methoxypsoralen on Pituitary-Gonad Axis and Ovarian Function in Mice
por: Fattahi, Esmail, et al.
Publicado: (2013)

Immune Effects of Trastuzumab
por: Nuti, Marianna, et al.
Publicado: (2011)

Trastuzumab Resistance: Role for Notch Signaling
por: Mehta, Kinnari, et al.
Publicado: (2009)

Trastuzumab emtansine: mechanisms of action and drug resistance
por: Barok, Mark, et al.
Publicado: (2014)

MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy
por: Hosseinzadeh, Aysooda, et al.
Publicado: (2022)

Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance
por: Mitani, Seiichiro, et al.
Publicado: (2020)

HER2 therapy: Molecular mechanisms of trastuzumab resistance
por: Nahta, Rita, et al.
Publicado: (2006)

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
por: Waller, Cornelius F., et al.
Publicado: (2021)

Topiramate and other kainate receptor antagonists for depression: A systematic review of randomized controlled trials
por: Shamabadi, Ahmad
Publicado: (2022)

YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development
por: Fujihara, Miwa, et al.
Publicado: (2021)

Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
por: Fiszman, Gabriel L., et al.
Publicado: (2011)

Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)
por: Diessner, J, et al.
Publicado: (2014)

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
por: Sadeghi, Saeed, et al.
Publicado: (2014)

Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine
por: Recondo, Gonzalo, et al.
Publicado: (2016)

Deciphering the Role of Insulin-Like Growth Factor-I Receptor in Trastuzumab Resistance
por: Nahta, Rita
Publicado: (2012)

Targeting Gastric Cancer with Trastuzumab: New Clinical Practice and Innovative Developments to Overcome Resistance
por: Roukos, Dimitrios H.
Publicado: (2009)

Identification of KLK10 as a therapeutic target to reverse trastuzumab resistance in breast cancer
por: Wang, Zhuo, et al.
Publicado: (2016)

Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer
por: Lammers, Philip E., et al.
Publicado: (2018)

Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It
por: Luque-Cabal, María, et al.
Publicado: (2016)

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer
por: Wong, Andrea L. A., et al.
Publicado: (2012)

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
por: Hunter, Francis W., et al.
Publicado: (2019)

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients
por: Cheng, Y C, et al.
Publicado: (2010)

Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo
por: Barok, Mark, et al.
Publicado: (2011)

Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation
por: Yamashita-Kashima, Yoriko, et al.
Publicado: (2020)

Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance
por: Bailey, Tameka A., et al.
Publicado: (2011)

Ketamine and Other Glutamate Receptor Modulating Agents for Treatment-Resistant Depression: A Systematic Review of Randomized Controlled Trials
por: Shamabadi, Ahmad, et al.
Publicado: (2022)

HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance
por: Nami, Babak, et al.
Publicado: (2017)

Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
por: Nami, Babak, et al.
Publicado: (2018)

Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma
por: Peiró, G, et al.
Publicado: (2014)

Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents
por: Wang, Zhen-hao, et al.
Publicado: (2022)

Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer
por: Vu, Thuy, et al.
Publicado: (2012)

An Investigation on the Status of Implementation of Communications and Information Management System (MCI) in Khorasan Razavi Hospitals
por: Shojaei, Saeed, et al.
Publicado: (2016)

Targeting HER2 in breast cancer: beyond trastuzumab
por: Winer, EP
Publicado: (2011)

Integrating Psychiatry and Medical Biotechnology as a Way to Achieve Scientific, Precision, and Personalized Psychiatry
por: Shamabadi, Ahmad, et al.
Publicado: (2021)

The neuropsychotropic effects of Crocus sativus L. (saffron): an overview of systematic reviews and meta-analyses investigating its clinical efficacy in psychiatric and neurological disorders
por: Shamabadi, Ahmad, et al.
Publicado: (2022)

erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy
por: ElSahwi, Karim S., et al.
Publicado: (2011)

Adjuvant trastuzumab: progress, controversies, and the steps ahead
por: Joy, A.A., et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_6a5q5k2ug26p5tqlgo55lmivhi